Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 117
Filter
1.
Org Lett ; 8(17): 3681-4, 2006 Aug 17.
Article in English | MEDLINE | ID: mdl-16898791

ABSTRACT

[structure: see text] New dicyanovinyl-substituted 1-(alkyl)aryl-2-(2'-thienyl)pyrroles 2 were synthesized and characterized. The solvatochromic behavior of the synthesized compounds was investigated. All the derivatives showed reversible oxidation and reduction on the CV time scale. The hyperpolarizabilities (beta) of compounds 2 were measured using hyper-Rayleigh scattering. The results are among the highest beta values reported for donor-acceptor-substituted thienylpyrroles.

2.
Clin Endocrinol (Oxf) ; 60(6): 750-7, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15163340

ABSTRACT

OBJECTIVES: There is evidence from recent controlled clinical studies that replacement therapy of hypothyroidism with T4 in combination with a small amount of T3 may improve the well-being of the patients. As the issue is still the subject of controversial discussion, our study was assigned to confirm the superiority of a physiological combination of thyroid hormones (absorbed molar ratio 14 : 1) over T4 alone with regard to mood states and cognitive functioning. DESIGN AND PATIENTS: After a run-in period with the T4 study medication for 4 weeks, a controlled, randomized, double-blind, two-period (each 12 weeks), cross-over study without washout between the treatment periods was performed in 23 hypothyroid patients (three males, 20 females, age 23-69 years, 21 subjects after surgery/radioiodine, two with autoimmune thyroiditis) to compare the effects of the previous individual T4 dose (100-175 micro g) with a treatment in which 5% of the respective T4 dose was substituted by T3. MEASUREMENTS: Standard hormonal characteristics and standardized psychological tests to quantify mood and cognitive performance were measured after the run-in period and at the end of each treatment period. In 12 subjects, the concentration-time profiles of fT3 and fT4 were compared after the last administration of the respective study medication. TSH, fT3 and fT4 were measured with immunological assays. CLINICAL RESULTS: Replacement therapy with T4 and T4/T3 was not different in all steady-state hormonal, metabolic and cardiovascular characteristics except for TSH, which was more suppressed after T4/T3. The efficacy of replacement therapy with the T4/T3 combination was not different from the T4 monotherapy with regard to all psychological test scores describing mood and cognitive functioning of the patients. Mood was even significantly impaired by the T4/T3 combination in eight subjects, with TSH < 0.02 mU/l, compared to patients with normal TSH (Beck Depression Inventory: 8.25 +/- 5.01 vs. 4.07 +/- 5.60, P = 0.026). PHARMACOKINETIC RESULTS: The area under the concentration-time curve (AUC(0-8h)) of fT3 was significantly higher after T4/T3 compared to the T4 monotherapy (42.8 +/- 9.03 pmol x h/l vs. 36.3 +/- 8.50 pmol x h/l, P < 0.05) and was significantly correlated to serum TSH (r(s) = -0.609, P < 0.05). After T4/T3, patients with a history of Graves' disease or autoimmune thyroiditis had significantly higher serum trough levels of fT3 whereas the fT4 concentrations were significantly lower in patients with a nonautoimmune background. CONCLUSION: Replacement therapy of hypothyroidism with T4 plus T3 does not improve mood and cognitive performance compared to the standard T4 monotherapy. There is even a higher risk of signs of subclinical hyperthyroidism associated with impaired well-being of the patients, which is clearly caused by significant fluctuations in the steady-state fT3 serum concentrations.


Subject(s)
Hypothyroidism/drug therapy , Thyroxine/therapeutic use , Triiodothyronine/therapeutic use , Adult , Affect/drug effects , Aged , Biological Availability , Cognition/drug effects , Cross-Over Studies , Double-Blind Method , Drug Therapy, Combination , Female , Humans , Hypothyroidism/blood , Hypothyroidism/psychology , Male , Middle Aged , Statistics, Nonparametric , Thyrotropin/blood , Thyroxine/adverse effects , Thyroxine/blood , Treatment Failure , Triiodothyronine/adverse effects , Triiodothyronine/blood
4.
Exp Clin Endocrinol Diabetes ; 111(4): 198-202, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12845557

ABSTRACT

Thyroid hormone receptors (TR) mediate the action of thyroid hormones. Genetic studies revealed that the individual TR isoforms possess different functions. In the present paper we studied the expression of the isoforms TRalpha1 and TRbeta1 in the murine pancreatic islet. TRalpha1 and TRbeta1 mRNA transcripts and proteins were detected in islets using reverse transcription-polymerase chain reaction and Western blotting analyses, respectively. In immunohistochemical studies individual cells in the periphery of islets were labelled using an anti-TRalpha1 antibody. No labelled cells were detected in the exocrine pancreas. A similar staining pattern was obtained with an anti-glucagon antibody, but not with an anti-insulin antibody, which suggests that TRalpha1 is mainly expressed in alpha-cells. In order to address a potential function of TRalpha1 in this cell type, the regulation of glucagon gene expression by triiodothyronine was studied in a glucagon-producing cell line by Northern blot analysis and transient transfection assays using glucagon promoter luciferase fusion gene constructs. In these assays, triiodothyronine did not regulate the glucagon mRNA level or the glucagon promoter activity. The predominant localization of TRalpha1 in pancreatic alpha-cells suggests that this receptor isoform mediates a specific, yet unknown, function of thyroid hormones in this cell type.


Subject(s)
Islets of Langerhans/metabolism , Thyroid Hormone Receptors alpha/metabolism , Animals , Cell Line , Glucagon/metabolism , Immunohistochemistry , In Vitro Techniques , Islets of Langerhans/cytology , Islets of Langerhans/drug effects , Mice , Thyroid Hormone Receptors beta/metabolism , Tissue Distribution , Triiodothyronine/pharmacology
5.
Biophys J ; 81(2): 814-26, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11463627

ABSTRACT

We previously concluded that the Kv2.1 K(+) channel inactivates preferentially from partially activated closed states. We report here that the Kv3.1 channel also exhibits two key features of this inactivation mechanism: a U-shaped voltage dependence measured at 10 s and stronger inactivation with repetitive pulses than with a single long depolarization. More surprisingly, slow inactivation of the Kv1 Shaker K(+) channel (Shaker B Delta 6--46) also has a U-shaped voltage dependence for 10-s depolarizations. The time and voltage dependence of recovery from inactivation reveals two distinct components for Shaker. Strong depolarizations favor inactivation that is reduced by K(o)(+) or by partial block by TEA(o), as previously reported for slow inactivation of Shaker. However, depolarizations near 0 mV favor inactivation that recovers rapidly, with strong voltage dependence (as for Kv2.1 and 3.1). The fraction of channels that recover rapidly is increased in TEA(o) or high K(o)(+). We introduce the term U-type inactivation for the mechanism that is dominant in Kv2.1 and Kv3.1. U-type inactivation also makes a major but previously unrecognized contribution to slow inactivation of Shaker.


Subject(s)
Neuropeptides/antagonists & inhibitors , Neuropeptides/metabolism , Potassium Channel Blockers , Potassium Channels, Voltage-Gated , Potassium Channels/metabolism , Allosteric Regulation/drug effects , Animals , Drosophila Proteins , Drosophila melanogaster , Electrophysiology , Kinetics , Membrane Potentials/drug effects , Models, Biological , Neuropeptides/genetics , Oocytes/drug effects , Oocytes/metabolism , Potassium Channels/genetics , RNA/genetics , RNA/metabolism , Shaker Superfamily of Potassium Channels , Shaw Potassium Channels , Tetraethylammonium/pharmacology , Xenopus laevis
6.
Am J Physiol Heart Circ Physiol ; 280(1): H354-60, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11123251

ABSTRACT

Idiopathic ventricular fibrillation (IVF) can cause sudden death in both adults and children. One form of IVF (Brugada syndrome), characterized by S-T segment elevation (STE) in the electrocardiogram, has been linked to mutations of SCN5A, the gene encoding the voltage-gated cardiac Na(+) channel. A missense mutation of SCN5A that substitutes glutamine for leucine at codon 567 (L567Q, in the cytoplasmic linker between domains I and II) is identified with sudden infant death and Brugada syndrome in one family. However, neither the functional effect of the L567Q mutation nor the molecular mechanism underlying the pathogenicity of the mutation is known. Patch-clamp analysis of L567Q channels expressed in human embryonic kidney cells revealed a marked acceleration and a negative shift in the voltage dependence of inactivation. Unlike other Brugada mutations, this phenotype was expressed independently of temperature or auxiliary beta(1)-subunits. These results support a proposed linkage between Brugada syndrome and some instances of sudden infant death and the hypothesis that reduced Na(+) conductance is the primary cause of IVF with STE.


Subject(s)
Sodium Channel Blockers , Ventricular Fibrillation/metabolism , Cell Line , Cloning, Molecular , Electrophysiology , Humans , Kinetics , Membrane Potentials , Mutagenesis , Mutation, Missense , Patch-Clamp Techniques , Sodium Channels/genetics , Temperature , Transfection , Ventricular Fibrillation/genetics
7.
J Mol Cell Cardiol ; 32(10): 1873-84, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11013131

ABSTRACT

Ventricular fibrillation leading to sudden cardiac death can occur even in the absence of structural heart disease. One form of this so-called idiopathic ventricular fibrillation (IVF) is characterized by ST segment elevation (STE) in the electrocardiogram. Recently we found that IVF with STE is linked to mutations of SCN5A, the gene encoding the cardiac sodium channel alpha -subunit. Two types of defects were identified: loss-of-function mutations that severely truncate channel proteins and missense mutations (e.g. a double mutation, R1232W and T1620M) that cause only minor changes in channel gating. Here we show that co-expression of the R1232W+T1620M missense mutant alpha -subunits in a mammalian cell line stably transfected with human sodium channel beta(1)-subunits results in a phenotype similar to that of the truncation mutants. In the presence of beta(1)subunits the expression of both ionic currents and alpha -subunit-specific, immunoreactive protein was markedly suppressed after transfection of mutant, but not wild-type alpha -subunits when cells were incubated at physiological temperature. Expression was partially restored by incubation at reduced temperatures. Our results reconcile two classes of IVF mutations and support the notion that a reduction in the amplitude of voltage-gated sodium conductance is the primary cause of IVF.


Subject(s)
Sodium Channel Blockers , Sodium Channels/genetics , Ventricular Fibrillation/metabolism , Animals , Cell Line , DNA, Complementary/metabolism , Electrophysiology , Humans , Immunoblotting , Ions , Kinetics , Models, Biological , Mutagenesis, Site-Directed , Mutation, Missense , NAV1.5 Voltage-Gated Sodium Channel , Oocytes/metabolism , Phenotype , Protein Folding , Protein Structure, Secondary , Protein Structure, Tertiary , Sodium Channels/chemistry , Sodium Channels/metabolism , Temperature , Time Factors , Transfection , Xenopus/embryology
8.
J Neuroimmunol ; 108(1-2): 136-46, 2000 Aug 01.
Article in English | MEDLINE | ID: mdl-10900347

ABSTRACT

Experimental autoimmune encephalomyelitis (EAE) is an autoimmune disease with pathological features reminiscent of those seen in multiple sclerosis and thus serves as an animal model for this disease. Inhibition of type IV phosphodiesterase (PDE IV) in animals with this disease has been shown to result in amelioration of disease symptoms. Here we describe the immunomodulatory activity of the novel potent and selective PDE IV inhibitor mesopram. In vitro, mesopram selectively inhibits the activity of type 1 helper T (Th1) cells without affecting cytokine production or proliferation of type 2 helper T (Th2) cells. Administration of mesopram to rodents inhibits EAE in various models. Clinically, EAE is completely suppressed by mesopram in Lewis rats. This is accompanied by a reduction of inflammatory lesions in spinal cord and brain. RT-PCR analysis revealed a marked reduction in the expression of interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) in the brains of these animals. Furthermore, the ex vivo production of Th1 cytokines by activated spleen cells derived from mesopram-treated animals is significantly reduced compared to vehicle-treated controls. Amelioration of the clinical symptoms is also observed during chronic EAE in mesopram-treated SJL mice as well as in relapsing-remitting EAE in SWXJ mice using a therapeutic treatment regimen. These data demonstrate the anti-inflammatory activity of mesopram and provide a rationale for its clinical development.


Subject(s)
3',5'-Cyclic-AMP Phosphodiesterases/antagonists & inhibitors , Encephalomyelitis, Autoimmune, Experimental/drug therapy , Enzyme Inhibitors/pharmacology , Enzyme Inhibitors/therapeutic use , Oxazoles/pharmacology , Oxazoles/therapeutic use , 3',5'-Cyclic-AMP Phosphodiesterases/metabolism , Acute Disease , Animals , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Cell Division/drug effects , Cells, Cultured , Central Nervous System/drug effects , Central Nervous System/immunology , Central Nervous System/metabolism , Central Nervous System/pathology , Chronic Disease , Cyclic Nucleotide Phosphodiesterases, Type 4 , Dose-Response Relationship, Drug , Down-Regulation/drug effects , Encephalomyelitis, Autoimmune, Experimental/immunology , Encephalomyelitis, Autoimmune, Experimental/pathology , Female , Humans , Inflammation/drug therapy , Inflammation/metabolism , Inflammation/pathology , Interferon-gamma/biosynthesis , Interferon-gamma/metabolism , Interleukin-5/biosynthesis , Interleukin-5/metabolism , Lymphocyte Activation/drug effects , Mice , Mice, Inbred Strains , Multiple Sclerosis/drug therapy , Rats , Rats, Inbred Lew , Recurrence , Spleen/drug effects , Spleen/immunology , Substrate Specificity , Th1 Cells/cytology , Th1 Cells/drug effects , Th1 Cells/immunology , Th1 Cells/metabolism , Th2 Cells/cytology , Th2 Cells/drug effects , Th2 Cells/immunology , Th2 Cells/metabolism , Tumor Necrosis Factor-alpha/metabolism
9.
Curr Pharm Des ; 6(7): 767-89, 2000 May.
Article in English | MEDLINE | ID: mdl-10828307

ABSTRACT

The introduction of oxygen atoms into different positions of the vitamin D side chain is described. By combining the arising 23-oxa and 25-oxa elements with other structural modifications (19-nor, iso-19-nor, 20-methyl, 20-ene, 20,21-cyclo) calcitriol analogs with remarkable levels of dissociation between beneficial acitivities on cell growth regulation and undesired hypercalcemia were identified. Structure-activity relations are elaborated in a very systematic outline of the Schering drug finding program in this particular class of vitamin D compounds.


Subject(s)
Antineoplastic Agents/chemical synthesis , Calcitriol/analogs & derivatives , Antineoplastic Agents/pharmacology , Cell Division/drug effects , HL-60 Cells , Humans , Hypercalcemia/chemically induced , Structure-Activity Relationship
10.
J Nat Prod ; 63(6): 825-9, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10869210

ABSTRACT

From the CH(2)Cl(2) extract of the sponge Hyrtios cf. erecta, collected from Fiji, two new sesterterpenes, 1 and 2, and the known compounds isodehydroluffariellolide (3), homofascaplysin A (4), and fascaplysin (5) were isolated. The structures of 1-5 were established employing 1D and 2D NMR spectroscopy and mass spectrometry. All NMR resonances of fascaplysin (5) have been unambiguously assigned. Evaluation of the biological activity of the extracts and pure compounds toward Plasmodium falciparum, Trypanosoma brucei subsp. rhodesiense, Trypanosoma cruzi, hepatitis A virus (HAV), several other microbial targets, and HIV-1-RT and p56(lck) tyrosine kinase revealed new activities for homofascaplysin (4) and fascaplysin (5), both being potently active in vitro against P. falciparum.


Subject(s)
Antimalarials/isolation & purification , Porifera/chemistry , Terpenes/isolation & purification , Animals , Antimalarials/chemistry , Antimalarials/pharmacology , Cells, Cultured , HIV Reverse Transcriptase/metabolism , Hepatovirus/drug effects , Indoles/chemistry , Indoles/isolation & purification , Indoles/pharmacology , Magnetic Resonance Spectroscopy , Plasmodium falciparum/drug effects , Sesterterpenes , Terpenes/chemistry , Terpenes/pharmacology , Trypanosoma brucei rhodesiense/drug effects , Trypanosoma cruzi/drug effects
11.
J Med Chem ; 43(9): 1762-9, 2000 May 04.
Article in English | MEDLINE | ID: mdl-10794693

ABSTRACT

We present a flow cytometry technique to evaluate the antioxidative properties of molecules on living cells, using a stable murine-murine hybridoma (Mark 3) cell line routinely cultured. Using this technique, intracellular superoxide anions and peroxides were evaluated with dihydrorhodamine (DHR-123) and dichlorofluorescein diacetate (DCFH-DA), respectively. When cells were first incubated for 10 min with either H(2)O(2) or the xanthine (X)/xanthine oxidase (XO) system, this flow cytometric technique was capable of evaluating the oxidative stress on cells. Twenty-one new analogues of ellipticine were synthesized and tested for their antioxidative properties compared to vitamin E and Ebselen used as references. A good statistical reflection of the antioxidative activities of these molecules was achieved by analyzing 35 000 cells in each experiment. Among them, the selenated molecule 18 was found to be 10 times more active than Ebselen but 10 000 times less active than vitamin E. Moreover, eight compounds showed glutathione peroxidase-like activities.


Subject(s)
Antioxidants/pharmacology , Animals , Azoles/chemistry , Azoles/pharmacology , Drug Evaluation, Preclinical , Ellipticines/pharmacology , Flow Cytometry , Fluoresceins , Glutathione Peroxidase/metabolism , Isoindoles , Mice , Organoselenium Compounds/chemistry , Organoselenium Compounds/pharmacology , Oxidative Stress/drug effects , Rats , Rhodamines , Spectrometry, Fluorescence , Tumor Cells, Cultured , Uncoupling Agents/pharmacology , Vitamin E/analogs & derivatives , Vitamin E/chemistry , Vitamin E/pharmacology
12.
Nervenarzt ; 71(1): 44-9, 2000 Jan.
Article in German | MEDLINE | ID: mdl-10695031

ABSTRACT

The term frontotemporal dementia is used to describe a primary degenerative form of dementia, which is characterized by typical clinical, neuropsychological, radiological and neuropathological features. Its onset is usually before the age of 65 years; manifestations before the age of 30 years have rarely been described. We report the case of a 22-year old man, who showed symptoms of behavioural disorder such as social retreat, lack of initiative, mental rigidity, progressive reduction of speech, and stereotyped behaviour. The neuropsychological examination revealed disorders of the executive functions. The cerebral MRI investigations showed bifrontal atrophies corresponding with hypoperfusion areas on the SPECT. Other investigations including EEG, evoked potentials, duplex ultrasonography, cerebral angiography, laboratory tests and cerebrospinal fluid were normal. In the present case report we discuss the clinical presentation of frontotemporal dementia with early onset.


Subject(s)
Frontal Lobe , Pick Disease of the Brain/diagnosis , Temporal Lobe , Temporal Lobe/physiopathology , Adult , Alzheimer Disease/diagnosis , Alzheimer Disease/pathology , Alzheimer Disease/physiopathology , Diagnosis, Differential , Diagnostic Imaging , Disease Progression , Electroencephalography , Frontal Lobe/pathology , Frontal Lobe/physiopathology , Humans , Male , Neuropsychological Tests , Pick Disease of the Brain/pathology , Pick Disease of the Brain/physiopathology , Temporal Lobe/pathology
13.
Circulation ; 101(5): 510-5, 2000 Feb 08.
Article in English | MEDLINE | ID: mdl-10662748

ABSTRACT

BACKGROUND: A mutation in the cardiac sodium channel gene (SCN5A) has been described in patients with the syndrome of right bundle branch block, ST-segment elevation in leads V1 to V3, and sudden death (Brugada syndrome). These electrocardiographic manifestations are transient in many patients with the syndrome. The present study examined arrhythmic risk in patients with overt and concealed forms of the disease and the effectiveness of sodium channel blockers to unmask the syndrome and, thus, identify patients at risk. METHODS AND RESULTS: The effect of intravenous ajmaline (1 mg/kg), procainamide (10 mg/kg), or flecainide (2 mg/kg) on the ECG was studied in 34 patients with the syndrome and transient normalization of the ECG (group A), 11 members of 3 families in whom a SCN5A mutation was associated with the syndrome and 8 members in whom it was not (group B), and 53 control subjects (group C). Ajmaline, procainamide, or flecainide administration resulted in ST-segment elevation and right bundle branch block in all patients in group A and in all 11 patients with the mutation in group B. A similar pattern could not be elicited in the 8 patients in group B who lacked the mutation or in any person in group C. The follow-up period (37+/-33 months) revealed no differences in the incidence of arrhythmia between the 34 patients in whom the phenotypic manifestation of the syndrome was transient and the 24 patients in whom it was persistent (log-rank, 0.639). CONCLUSIONS: The data demonstrated a similar incidence of potentially lethal arrhythmias in patients displaying transient versus persistent ST-segment elevation and right bundle branch block, as well as the effectiveness of sodium channel blockers to unmask the syndrome and, thus, identify patients at risk.


Subject(s)
Anti-Arrhythmia Agents/therapeutic use , Bundle-Branch Block/complications , Death, Sudden, Cardiac/etiology , Sodium Channel Blockers , Adult , Bundle-Branch Block/genetics , Electrocardiography/drug effects , Female , Follow-Up Studies , Humans , Male , Middle Aged , NAV1.5 Voltage-Gated Sodium Channel , Pedigree , Risk Factors , Sodium Channels/genetics
15.
Can J Microbiol ; 45(2): 106-15, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10380643

ABSTRACT

Experiments have been performed to screen eight microbial commercial products that, according to the manufacturers, are able to degrade crude oil. This study compared the crude oil biodegradation activity of commercial inocula with that of natural inocula (activated sludge and tropical aquarium water). Some of the latter were previously adapted to the crude oil as the only carbon source. Nutrients and sorbents in the commercial formulations were eliminated, and each inoculum was precultured on marine yeast extract medium. Crude oil biodegradability tests were conducted with close initial substrate concentration to initial bacterial concentration ratios (S0/X0) of 0.94 g of crude oil/10(9) CFU, which allowed a comparison of biodegradation activity. The inocula oxidized the crude oil after a short lag time of less than 3-18 days. After that time, the rate of oxidation varied between 45 and 244 mg O2/(L.day). Crude oil biodegradation after a 28-day test was effective only for 10 out of 12 inocula (from 0.1 to 25% in weight). Biodegradation mainly corresponded to the saturated fraction of the crude oil; the asphaltene fraction was never significantly biodegraded. Our results led to the conclusion that natural inocula, either adapted or not adapted to crude oil, were the most active (from 16 to 25% of loss in crude oil weight) and only one commercial inoculum was able to degrade 18% of the crude oil. Other inocula had a biodegradation activity ranging from 0.1 to 14%.


Subject(s)
Bacteria/metabolism , Industrial Microbiology , Petroleum/metabolism , Biodegradation, Environmental , Time Factors
16.
Arzneimittelforschung ; 48(8): 840-9, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9748714

ABSTRACT

Metabolism of arachidonic acid through the 5-lipoxygenase (LO) pathway generates compounds that stimulate osteoclastic bone resorption; since LO metabolites might play a role in bone loss due to excessive resorption it was tried to develop a series of antiresorptive agents starting from an already known LO inhibitor. Of the 35 compounds synthesized, 11 strongly inhibited (10 mumol/l) retinoic acid-induced bone resorption in cultured mouse calvariae; they were also tested for their effect on LO activity using rat peritoneal neutrophils, but no correlation could be drawn between inhibition of LO and bone resorption. Other pathways, still to be identified, must therefore be targeted by these compounds even though LO inhibition might contribute to their effects on bone. Two compounds selected for further studies were found active on parathyroid hormone-induced osteolysis, while they had no effect on basal resorption; they must, therefore, act at some key point in the process of activation of osteoclastic resorption. This series of compounds may represent a new way for the treatment of bone loss due to excessive resorption.


Subject(s)
Bone Resorption/drug therapy , Lipoxygenase Inhibitors/chemical synthesis , Thiophenes/chemical synthesis , Animals , Animals, Newborn , Bone Development/drug effects , Female , In Vitro Techniques , Lipoxygenase/metabolism , Lipoxygenase Inhibitors/chemistry , Lipoxygenase Inhibitors/pharmacology , Magnetic Resonance Spectroscopy , Male , Mice , Neutrophils/drug effects , Neutrophils/enzymology , Peritoneal Cavity/cytology , Rats , Rats, Inbred Lew , Skull/drug effects , Skull/growth & development , Spectrophotometry, Infrared , Structure-Activity Relationship , Thiophenes/chemistry
17.
Am J Physiol ; 274(6): C1501-10, 1998 06.
Article in English | MEDLINE | ID: mdl-9696692

ABSTRACT

We have determined the effects of coexpression of Kv2.1 with electrically silent Kv5.1 or Kv6.1 alpha-subunits in Xenopus oocytes on channel gating. Kv2.1/5.1 selectively accelerated the rate ofinactivation at intermediate potentials (-30 to 0 mV), without affecting the rate at strong depolarization (0 to +40 mV), and markedly accelerated the rate of cumulative inactivation evoked by high-frequency trains of short pulses. Kv5.1 coexpression alsoslowed deactivation of Kv2.1. In contrast, Kv6.1 was much less effective in speeding inactivation at intermediate potentials, had a slowing effect on inactivation at strong depolarizations, and had no effect on cumulative inactivation. Kv6.1, however, had profound effects on activation, including a negative shift of the steady-state activation curve and marked slowing of deactivation tail currents. Support for the notion that the Kv5.1's effects stem from coassembly of alpha-subunits into heteromeric channels was obtained from biochemical evidence of protein-protein interaction and single-channel measurements that showed heterogeneity in unitary conductance. Our results show that Kv5.1 and Kv6.1 function as regulatory alpha-subunits that when coassembled with Kv2.1 can modulate gating in a physiologically relevant manner.


Subject(s)
Action Potentials/physiology , Potassium Channels, Voltage-Gated , Potassium Channels/metabolism , Potassium Channels/physiology , Action Potentials/genetics , Animals , Delayed Rectifier Potassium Channels , Gene Expression , Oocytes/physiology , Patch-Clamp Techniques , Potassium Channels/genetics , Recombinant Fusion Proteins , Shab Potassium Channels , Transfection , Xenopus
18.
Biophys J ; 74(4): 1779-89, 1998 Apr.
Article in English | MEDLINE | ID: mdl-9545040

ABSTRACT

We report here several unusual features of inactivation of the rat Kv2.1 delayed rectifier potassium channel, expressed in Xenopus oocytes. The voltage dependence of inactivation was U-shaped, with maximum inactivation near 0 mV. During a maintained depolarization, development of inactivation was slow and only weakly voltage dependent (tau = 4 s at 0 mV; tau = 7 s at +80 mV). However, recovery from inactivation was strongly voltage dependent (e-fold for 20 mV) and could be rapid (tau = 0.27 s at -140 mV). Kv2.1 showed cumulative inactivation, where inactivation built up during a train of brief depolarizations. A single maintained depolarization produced more steady-state inactivation than a train of pulses, but there could actually be more inactivation with the repeated pulses during the first few seconds. We term this phenomenon "excessive cumulative inactivation." These results can be explained by an allosteric model, in which inactivation is favored by activation of voltage sensors, but the open state of the channel is resistant to inactivation.


Subject(s)
Models, Biological , Potassium Channel Blockers , Potassium Channels, Voltage-Gated , Potassium Channels , Allosteric Regulation , Animals , Biophysical Phenomena , Biophysics , Delayed Rectifier Potassium Channels , Female , In Vitro Techniques , Kinetics , Membrane Potentials , Oocytes/metabolism , Patch-Clamp Techniques , Rats , Recombinant Proteins/antagonists & inhibitors , Shab Potassium Channels , Xenopus
19.
Nature ; 392(6673): 293-6, 1998 Mar 19.
Article in English | MEDLINE | ID: mdl-9521325

ABSTRACT

Ventricular fibrillation causes more than 300,000 sudden deaths each year in the USA alone. In approximately 5-12% of these cases, there are no demonstrable cardiac or non-cardiac causes to account for the episode, which is therefore classified as idiopathic ventricular fibrillation (IVF). A distinct group of IVF patients has been found to present with a characteristic electrocardiographic pattern. Because of the small size of most pedigrees and the high incidence of sudden death, however, molecular genetic studies of IVF have not yet been done. Because IVF causes cardiac rhythm disturbance, we investigated whether malfunction of ion channels could cause the disorder by studying mutations in the cardiac sodium channel gene SCN5A. We have now identified a missense mutation, a splice-donor mutation, and a frameshift mutation in the coding region of SCN5A in three IVF families. We show that sodium channels with the missense mutation recover from inactivation more rapidly than normal and that the frameshift mutation causes the sodium channel to be non-functional. Our results indicate that mutations in cardiac ion-channel genes contribute to the risk of developing IVF.


Subject(s)
Mutation , Sodium Channels/genetics , Ventricular Fibrillation/genetics , Action Potentials , Animals , DNA Mutational Analysis , Electrocardiography , Electrophysiology , Female , Frameshift Mutation , Humans , Ion Channel Gating/genetics , Kinetics , Male , NAV1.5 Voltage-Gated Sodium Channel , Pedigree , Polymorphism, Single-Stranded Conformational , Protein Structure, Secondary , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Sodium Channels/chemistry , Sodium Channels/metabolism , Ventricular Fibrillation/etiology , Ventricular Fibrillation/metabolism , Xenopus
20.
Am J Physiol ; 274(2): H477-87, 1998 02.
Article in English | MEDLINE | ID: mdl-9486250

ABSTRACT

Inherited long Q-T syndrome is a ventricular arrhythmia associated with delayed repolarization and the risk of sudden death. The chromosome 3-linked form of the disease (LQT3) is associated with mutations in the cardiac Na+ channel (N1325S or R1644H; or deletion of residues 1,505-1,507, delta KPQ) that increase late inward currents and may cause delayed repolarization. Late currents arise from dispersed reopenings (N1325S and R1644H) or from reopenings combined with prolonged bursts (delta KPQ). Therefore, we tested whether lidocaine blockade of late current varied among the different LQT3 mutant channels. We found that lidocaine preferentially blocked late over peak current and that the blockade was equally effective in all three channels, expressed in Xenopus oocytes. Lidocaine inhibited both dispersed reopenings and bursting in single channels without affecting mean open times. In the absence of drug, inactivating prepulses inhibited bursting but not dispersed reopenings. We suggest that lidocaine block of late current in LQT3 channels acts via a common mechanism involving stabilization of inactivation. Therefore, blockers that target the inactivated state may be effective therapeutic agents in all three biophysical phenotypes of LQT3.


Subject(s)
Arrhythmias, Cardiac/genetics , Lidocaine/pharmacology , Sodium Channels/genetics , Animals , Anti-Arrhythmia Agents/pharmacology , Chromosomes, Human, Pair 3 , Electric Conductivity , Female , Gene Deletion , Gene Expression , Heart Ventricles , Humans , Mutagenesis, Site-Directed , Mutation , Myocardium/chemistry , Oocytes/metabolism , Recombinant Proteins , Sodium Channels/drug effects , Sodium Channels/physiology , Transfection , Xenopus
SELECTION OF CITATIONS
SEARCH DETAIL